AR gene amplifications, which have been detected in up to 60% of pretreated CRPC patients [17], are also responsible for tumor progression despite optimal ADT; in fact, they determine higher expression of AR in prostate cancer tissue with consequent cell growth despite low androgen levels [18]. The gene discussed is AR; the disease is neoplasm.